SPATAX: Clinical and Genetic Analysis of Cerebellar Ataxias and Spastic Paraplegias

Study acronym: Spatax
StatusCompleted
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv14
  2. Notable Study completion date changed from estimate of Dec 2012 to Dec 30, 2020v13 Show 5 more changesShow less
    • Start date: Jul 2003 to Feb 10, 2004
    • Trial status: Recruiting to Completed
    • Primary completion date: Dec 2020
    • Site details revised at 27 of 27 sites
    • Collaborators: 2 to 3
  3. 3 versions Re-verified since Apr 26, 2011, no change to tracked fieldsv10-v12
  4. Minor Study sites: 18 to 27
    • Study completion date: Dec 2007 to Dec 2012
    • Collaborators: 1 to 2
    • Publications: 33 to 45
    v9
  5. Minor Study completion date: Oct 2005 to Dec 2007
    • Publications: 27 to 33
    v8
Show 6 earlier versionsHide 6 earlier versions
  1. Minor Publications: 29 to 27v7
  2. Minor Publications: 27 to 29v6
  3. Minor Publications: 25 to 27v5
  4. Minor Publications: 18 to 25v4
  5. Minor Study title expanded, about 10 words
    • Eligibility criteria shortened, about 2 words
    v3
  6. Minor Publications: 12 to 18v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Cerebellar ataxias (CA) and spastic paraplegias (SP) are genetically and clinically very heterogeneous. More than 40 loci are already known but the number of phenotypes is even greater suggesting further genetic heterogeneity. These progressive disorders are often severe and fatal, due to the absence of specific therapy. The SPATAX network combines the experience of European clinicians and scientists working on these groups of diseases. Over the past year, they have assembled the largest collection of families and achieved a number of tasks (initiation of a clinical and genetic database, distribution of DNA to participating laboratories, mapping of three new loci, and refinement of several loci). In addition to clinicians from Europe and Mediterranean countries, who play a major role in collecting families according to evaluation tools developed and validated by the SPATAX members, the group includes major European laboratories devoted to the elucidation of the molecular basis of these disorders. Each laboratory will centralize all families with a subtype of autosomal recessive (AR) CA (n=116) or SP (n=207) in order to efficiently map and identify the responsible gene(s). Genome-wide scans are already underway in 61 families. Given the expertise of the participants, the researchers expect to map and identify several genes during the course of this project. The spectrum of mutations and phenotype/genotype correlations will be analysed thanks to this unique series of patients with various phenotypes. The knowledge gained will be immediately applicable to patients in terms of improved positive diagnosis, follow-up and appropriate genetic counselling. In the long term, models for genetic entity will be developed in order to understand the pathophysiology and to identify new targets for treatment. The series of patients assembled and the precise knowledge of natural history will facilitate the implantation of therapeutic trials based on rational approaches.
Trial Details
NCT Number NCT00140829
Lead Sponsor Institut National de la Santé Et de la Recherche Médicale, France
Collaborators: Institut des Maladies Rares, National Research Agency, France, Paris Brain Institute (ICM)
Conditions
(from sponsor)
Cerebellar Ataxias, Spastic Paraplegias
Related terms Cerebellar Ataxia, Paraplegia
Enrollment 6,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov